Empagliflozin + Metformin Tablet Franchise in Ahmedabad

Anti-Diabetic Combination Tablet Supplier in Bangalore

Dual Therapy Diabetes Tablet Distributor in Hyderabad

Oral Anti-Diabetic Tablet Franchise Opportunity in Jaipur

Type-2 Diabetes Medicine Stockist in Mumbai
Anti-Diabetic Tablet Export & Manufacturing in Chandigarh

Home/Products /empagliflozin-5mg-metformin-850mg-tablet

Emplozin M 5-850 Tablet

Composition : Empagliflozin (5mg) + Metformin (850mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹0/-

Please Contact For Best Price

Emplozin M 5/850 Tablet is a scientifically formulated dual-drug oral therapy combining Empagliflozin 5mg and Metformin 850mg, designed to provide effective blood sugar control in patients with type-2 diabetes mellitus.

Empagliflozin helps lower blood glucose by promoting renal glucose excretion, while Metformin improves insulin sensitivity and reduces hepatic glucose production. Together, they provide balanced management of fasting and postprandial blood sugar levels.

This combination is widely prescribed for patients requiring dual therapy with improved metabolic control, offering efficacy along with a favorable safety profile. Its once-daily dosing supports patient adherence in chronic diabetes management.

Adding Emplozin M 5/850 Tablet to your diabetes and metabolic-care portfolio strengthens your market offerings, creating strong opportunities in retail pharmacy supply, hospital procurement, institutional distribution, export channels, and third-party manufacturing. Its high prescription demand ensures consistent commercial performance.

Read More

About the Product

Emplozin M 5/850 Tablet is a scientifically formulated dual-drug oral therapy combining Empagliflozin 5mg and Metformin 850mg, designed to provide effective blood sugar control in patients with type-2 diabetes mellitus.

Empagliflozin helps lower blood glucose by promoting renal glucose excretion, while Metformin improves insulin sensitivity and reduces hepatic glucose production. Together, they provide balanced management of fasting and postprandial blood sugar levels.

This combination is widely prescribed for patients requiring dual therapy with improved metabolic control, offering efficacy along with a favorable safety profile. Its once-daily dosing supports patient adherence in chronic diabetes management.

Adding Emplozin M 5/850 Tablet to your diabetes and metabolic-care portfolio strengthens your market offerings, creating strong opportunities in retail pharmacy supply, hospital procurement, institutional distribution, export channels, and third-party manufacturing. Its high prescription demand ensures consistent commercial performance.

Some patients may experience nausea, diarrhea, abdominal discomfort, increased urination, dizziness, or headache. Rarely, hypoglycemia (especially when used with other antidiabetic agents), urinary tract infections, genital infections, or lactic acidosis may occur.

Emplozin M 5/850 Tablet is indicated for the management of type 2 diabetes mellitus in patients who require dual therapy to achieve effective glycemic control when diet and exercise alone are insufficient.

Use strictly under medical supervision. Regular monitoring of blood glucose and kidney function is recommended. Avoid use in patients with severe renal impairment or metabolic acidosis. Follow the prescribed dosage and lifestyle guidance carefully.

Store in a cool, dry place below 25°C, protected from light and moisture. Keep out of reach of children.

Get in Touch